Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Breast Cancer, CIPN - Chemotherapy-Induc...
Phase PHASE2, PHASE3
Enrollment 160
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this research is to assess whether hyperbaric oxygen therapy can alleviate the symptoms of Nab-paclitaxel-induced peripheral neuropathy and improve patient-reported quality of life.

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Hyperbaric oxygen treatment — Patients who meet the inclusion criteria will be enrolled and given hyperbaric oxygen intervention, one per day for 90-120 minutes, for a total of 20-30 hyperbaric oxygen treatments (100% oxygen at a pressure of 2.0 ATA)
  • Other: Standard Care (in control arm) — Standard care

Primary Outcomes

  • EORTC QLQ-CIPN20 subscales (baseline, after intervention (week 6) and 1 , 3 , 6 and 12month after the intervention ended.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2026-09-29
Completion: 2027-12-31
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Guangdong Provincial People's Hospital
Principal Investigators:
  • Kun Wang (PRINCIPAL_INVESTIGATOR) - Guangdong Provincial People's Hospital
Contact Information
Study Contact:
Kun Wang, PhD
+8615989223200
gzwangkun@126.com
Yingcong Lin, Master of Medicine
+8618666885689
18666885689@163.com
Wang Kun PhD, Doctor
15989223200
gzwangkun@126.com
Guangdong Provincial People's Hospital
Interventions
  • Device: Hyperbaric oxygen treatment — Patients who meet the inclusion criteria will be enrolled and given hyperbaric oxygen intervention, one per day for 90-120 minutes, for a total of 20-30 hyperbaric oxygen treatments (100% oxygen at a pressure of 2.0 ATA)
  • Other: Standard Care (in control arm) — Standard care
Study Locations (2 sites)
Guangdong Provincial People's Hospital, Guangzhou, Guangdong 510080 China
Guangdong Provincial People's Hospital, Guangzhou, Guangdong China
Eligibility Criteria
Inclusion Criteria: 1. aged ≥ 18 years and ≤ 75 years, female 2. early-stage breast cancer or locally advanced breast cancer 3. Patients who have completed adjuvant or neoadjuvant chemotherapy with nab-paclitaxel 4. The patient developed nab-paclitaxel induced peripheral neuropathy (Nab-PIPN), as defined by meeting any of the following criteria: Patient Neurotoxicity Questionnaire (PNQ) score ≥ Grade B, NCI-CTCAE (sensory and motor neuropathy) grade ≥ 1, or neuropathic pain score ≥ 4/10. 5. The patient voluntarily participated in this study, provided written informed consent, and agreed to cooperate with follow-up assessments. Exclusion Criteria: 1. Patients who have previously taken drugs that may affect the evaluation of Nab-PIPN symptoms, such as duloxetine, venlafaxine, gabapentin, pregabalin, and amitriptyline. 2. Patients with any other pathological conditions or diseases that could affect Nab-PIPN assessment, including alcoholic peripheral neuropathy, uremic peripheral neuropathy, diabetic peripheral neuropathy, thiamine deficiency-related peripheral neuropathy, and chronic axonal peripheral neuropathy of unknown etiology. 3. Patients who have contraindications for hyperbaric oxygen therapy, including pulmonary disorders (severe chronic obstructive pulmonary disease, bullous lung disease, acute or chronic pulmonary infection, uncontrolled asthma, untreated pneumothorax), history of previous middle ear surgery, middle ear diseases (eustachian tube dysfunction, recurrent vertigo), and ocular conditions (retinal detachment). 4. Patients with any disease history that may affect compliance, including severe mental disorders, cognitive impairment, substance abuse or addiction. 5. Karnofsky Performance Status score \< 80 6. Patients with any other conditions that the investigator deems unsuitable for participation in the study.
Conditions Breast Cancer, Breast Surgery, Postopera...
Phase NA
Enrollment 126
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This randomized controlled trial aims to evaluate the effects of pranayama and pursed-lip breathing exercises on postoperative pain, anxiety, and vital signs in patients undergoing breast surgery. Postoperative pain and anxiety are common problems that can negatively affect recovery, physiological stability, and overall well-being. Non-pharmacological interventions such as breathing exercises may help reduce these adverse outcomes and support recovery. Participants will be randomly assigned to one of three groups: a pranayama breathing exercise group, a pursed-lip breathing exercise group, or a control group receiving routine postoperative care. Breathing exercises will be performed three times daily for five minutes. Outcomes including pain, anxiety, and vital signs will be measured at baseline (pretest), postoperative day 1, and postoperative day 2. The findings of this study are expected to provide evidence on the effectiveness of breathing exercises as supportive nursing interventions in the postoperative care of breast surgery patients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Pranayama Breathing Exercise — Participants perform pranayama breathing exercises (Nadi Shodhana technique) starting at the 4th postoperative hour. The exercise is performed three times daily for two consecutive days. Each session lasts approximately five minutes and is administered in addition to routine postoperative care. The breathing technique involves slow, controlled inhalation and exhalation through alternate nostrils to improve respiratory function and relaxation.
  • Behavioral: Pursed-Lip Breathing Exercise — Participants perform pursed-lip breathing exercises starting at the 4th postoperative hour. The exercise is performed three times daily for two consecutive days, with each session lasting approximately five minutes. Participants inhale slowly through the nose and exhale through pursed lips to prolong exhalation and improve ventilation, in addition to routine postoperative care.

Primary Outcomes

  • Postoperative Pain Level (Postoperative day 1, and postoperative day 2.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-13
Completion: 2027-04-27
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 126 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ondokuz Mayıs University
Principal Investigators:
  • Özge İşeri, Assistant Professor (PRINCIPAL_INVESTIGATOR) - Ondokuz Mayıs University, Faculty of Health Sciences, Department of Nursing, Samsun, Türkiye
Contact Information
Study Contact:
Gonca AKBAŞ, MSc
5312716024
akbasgonca0@gmail.com
Özge İşeri, Assistant Professor
5433997496
ozgepekiniseri@gmail.com
Gonca Akbaş, MSc
+90 531 271 6024
akbasgonca0@gmail.com
University of Health Sciences Haydarpasa Numune Training and Research Hospital
Interventions
  • Behavioral: Pranayama Breathing Exercise — Participants perform pranayama breathing exercises (Nadi Shodhana technique) starting at the 4th postoperative hour. The exercise is performed three times daily for two consecutive days. Each session lasts approximately five minutes and is administered in addition to routine postoperative care. The breathing technique involves slow, controlled inhalation and exhalation through alternate nostrils to improve respiratory function and relaxation.
  • Behavioral: Pursed-Lip Breathing Exercise — Participants perform pursed-lip breathing exercises starting at the 4th postoperative hour. The exercise is performed three times daily for two consecutive days, with each session lasting approximately five minutes. Participants inhale slowly through the nose and exhale through pursed lips to prolong exhalation and improve ventilation, in addition to routine postoperative care.
Study Locations (1 sites)
University of Health Sciences Haydarpasa Numune Training and Research Hospital, Istanbul, Istanbul 34668 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years and older * Able to communicate effectively * Patients undergoing elective surgery for the first time, including radical mastectomy, modified radical mastectomy, or simple mastectomy Exclusion Criteria: * Patients undergoing breast-conserving surgery * Patients who develop any postoperative complications, such as bleeding or anesthesia-related complications * Individuals with cognitive or mental impairments * Patients who wish to withdraw from the study at any stage * Patients with hearing or speech impairments * Patients with a psychiatric diagnosis or those using psychiatric medications * Patients unable to comply with breathing exercises
Conditions Breast Neoplasms
Phase NA
Enrollment 34
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

Elderly patients with advanced triple-positive breast cancer have the characteristics of low physical status and poor treatment tolerance. Therefore, such patients are often unable to tolerate more toxic chemotherapy regimen, and it is particularly important to choose a highly effective and low-toxic treatment regimen. However, few studies have paid attention to the treatment of such patients in the past. Pyrrotinib is a small molecule, irreversible, panerbb receptor tyrosine kinase inhibitor, which was independently developed by our country and has shown excellent efficacy in second-line anti-HER2 treatment of breast cancer, and has become the second-line standard treatment choice for advanced HER2-positive breast cancer. In addition, PHILA study results showed that the mPFS of pyrrotinib group reached 24 months. Compared with the control group, the duration of 10 months was significantly extended, indicating the significant efficacy of pyrrotinib in the first-line treatment of advanced HER2-positive breast cancer. Darsili is a CDK4/6 inhibitor independently developed in China, which has been reconstructed and optimized in molecular structure, and has become a new CDK4/6 inhibitor with more powerful modification by introducing piperidine structure through replacement of classical electronic and other panbody. The results of DAWNA-2 study indicated that the mPFS of Dalsily combined AI group reached 30.6 months, which was significantly longer than 18.2 months of the control group, and was the longest in similar studies. MUKDEN01 study, for the first time, tried the efficacy of pyrrotinib + letrozole + Dalsily regimen in the new adjuvant therapy of TPBC patients, and the results showed that ORR reached 87.4%, CR rate was 30.4%, and pCR rate was 35.4%. Therefore, to further confirm the efficacy and safety of this protocol in elderly patients with advanced triple positive breast cancer, we intend to conduct this study. This is a prospective, single-arm, single-center clinical trial in which participants were treated with darcilide +AI (letrozole/anastrozole/exemestane) + pyrrotinib until disease progression, toxicity became intolerable, informed consent was withdrawn, or investigator judgment required discontinuation. The successful development of this study provides a new direction for the first-line treatment of elderly advanced triple-positive breast cancer.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Darcilide +AI (letrozole/anastrozole/Exemestane) + pyrrotinib — Darcilie: 125mg orally once a day, taken for 21 days and stopped for 7 days, 28 days as a cycle. AI: Letrozole: 2.5mg orally once daily, or anastrozole 1mg orally once daily, or exemestane 25mg orally once daily. Pyrrotinib: Initial dose of 240mg in the first week, if diarrhea and other side effects can be tolerated, 320 mg can be added in the second week, once a day, oral administration within 30 minutes after breakfast, 21 days for 1 cycle All investigational drugs should be used for disease progression or when patients have an intolerable adverse reaction or are withdrawn from the study for other reasons. Oral pyrrotinib is recommended along with prophylactic antidiarrheal medication. Antidiarrheal regimen 1: Oral imodium (2 tablets/times, 2 times a day) from the first week, 1 tablet, 2 times a day from the second week. Antidiarrheal regimen 2: montmorillonite powder (3 times a day, 1 pack/time)+ whole intestine sheng (3 pills/time 2 times a day).

Primary Outcomes

  • Progression Free Survival (29 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-01
Completion: 2026-12-01
Eligibility
Age: 65 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 34 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital of Soochow University
Contact Information
Study Contact:
Hui Wang
13913501391
whuisd@163.com
Hui Wang
13913501391
whuisd@163.com
The Second Affiliated Hospital of Soochow University
Shushu Zhang
18936081534
xyzss567@163.com
The Second Affiliated Hospital of Soochow University
Interventions
  • Drug: Darcilide +AI (letrozole/anastrozole/Exemestane) + pyrrotinib — Darcilie: 125mg orally once a day, taken for 21 days and stopped for 7 days, 28 days as a cycle. AI: Letrozole: 2.5mg orally once daily, or anastrozole 1mg orally once daily, or exemestane 25mg orally once daily. Pyrrotinib: Initial dose of 240mg in the first week, if diarrhea and other side effects can be tolerated, 320 mg can be added in the second week, once a day, oral administration within 30 minutes after breakfast, 21 days for 1 cycle All investigational drugs should be used for disease progression or when patients have an intolerable adverse reaction or are withdrawn from the study for other reasons. Oral pyrrotinib is recommended along with prophylactic antidiarrheal medication. Antidiarrheal regimen 1: Oral imodium (2 tablets/times, 2 times a day) from the first week, 1 tablet, 2 times a day from the second week. Antidiarrheal regimen 2: montmorillonite powder (3 times a day, 1 pack/time)+ whole intestine sheng (3 pills/time 2 times a day).
Study Locations (1 sites)
The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000 China
Eligibility Criteria
Inclusion Criteria: * 1.Age: ≥65 years old; 2. Histologically confirmed stage IV TPBC; 3. Without prior treatment, adjuvant endocrine therapy and anti-HER2 therapy should be completed for more than one year; 4.TPBC is defined as HER2-positive (3+ by immunohistochemistry, or 2+ by fluorescence in situ hybridization), ER-positive (more than 10% of tumor cells expressed estrogen receptor by immunohistochemistry), and PR-positive (at least 1% of tumor cells expressed progesterone receptor by immunohistochemistry) breast cancer; 5.ECOG score is 0-3 points; 6. Expected survival ≥12 weeks; 7. Normal function of major organs: 1. Blood routine: Neutrophil (ANC) ≥1.5×109/L; Platelet count (PLT) ≥75×109/L; Hemoglobin (Hb) ≥90 g/L; 2. Blood biochemistry: Total bilirubin (TBIL) ≤1.5× upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0×ULN; Alkaline phosphatase ≤2.5×ULN; Urea or urea nitrogen (BUN) and creatinine (Cr) ≤1.5×ULN; 3. Heart color ultrasound: Left ventricular ejection fraction (LVEF) ≥50%. Exclusion Criteria: * 1\. Breast cancer with no evaluable lesions such as inflammation or occult; 2. Other malignancies within five years 3. Received other tyrosine kinase inhibitors, anti-HER2 treatment and T-DM1 treatment less than one year ago; 4. Patients with intestinal obstruction or fasting, gastrointestinal history, with diarrhea as the main symptom; 5. Suffering from mental illness or psychotropic substance abuse, unable to cooperate; 6. Pregnant or lactating women; 7. Participants considered unsuitable for inclusion by the researchers.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

Severe but also moderate toxicities after curative-intent radiotherapy (RT), such as a poor cosmetic outcome following breast cancer can have a negative impact on quality of life and a marked effect on subsequent psychological outcome. Nevertheless, current practice standards commonly prescribe radiation dose and volume without regard to individual radiosensitivity. In that context, a normal tissue radiosensitivity test that includes a rapid (72 h) radiosensitivity assay based on flow cytometric assessment of radiation-induced CD8 T-lymphocyte apoptosis (RILA) and other significant clinical parameters (multifactorial nomogram) was developed. Omission of radiotherapy has been suggested when luminal A tumor subtype is combined with clinical and pathologic factors defining a subgroup of patients with a low risk of ipsilateral breast recurrence. In this group, the benefits of radiotherapy are small \[6\]. Reduction of the breast irradiated volume is also a possibility that has been tested and published using IORT, brachytherapy or external beam radiotherapy. Hypofractionation has been adapted to breast cancer radiotherapy. Overall, all recent clinical trials \[13, 14\] showed only few late effects when hypofractionation was delivered to the whole breast (WB). These results reinforce the need of patients' selection using the NovaGray Breast® test. Our hypothesis is therefore that the different techniques (volume reduction or hypofractionation) as well as radiotherapy omission will significantly reduce grade ≥2 bf+ in a personalized approach (driven by a predictive assay of late effects) compared to WB hypofractionation in a selected population at low risk of breast recurrence. We would like to establish a prospective evaluation of daily practice including the individual radiosensitivity test to the decision of daily practice

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Interventions / Regimen

  • Radiation: Radiotherapy — curative-intent radiotherapy

Primary Outcomes

  • Acute and late breast fibrosis rate (Until the study completion: 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-05-23
Completion: 2026-06
Eligibility
Age: 65 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Principal Investigators:
  • Céline BOURGIER, MD (STUDY_CHAIR) - Institut Régional du Cancer de Montpellier (ICM)
Contact Information
Study Contact:
Jean-Pierre BLEUSE, MD
0467613102
DRCI-icm105@icm.unicancer.fr
Jean-Pierre BLEUSE, MD
0467613102
DRCI-icm105@icm.unicancer.fr
Institut Régional du Cancer de Montpellier
Céline BOURGIER, MD
Institut Régional du Cancer de Montpellier
Interventions
  • Radiation: Radiotherapy — curative-intent radiotherapy
Study Locations (1 sites)
Institut Régional du Cancer de Montpellier, Montpellier, Occ 34298 France
Eligibility Criteria
Inclusion Criteria: 1. Compliant women ≥ 65 years old. 2. Conservative breast cancer surgery. 3. T1-T2; N sentinel negative/N0. 4. Luminal A tumors. 5. Tumor negative margins. 6. Indication of whole breast irradiation only. 7. Extension evaluation of disease will be proven negative (M0). 8. Must be geographically accessible for follow-up. 9. Written and dated informed consent. 10. Affiliated to the French social security system. Exclusion Criteria: 1. Patients with distant metastases. 2. Indications of node irradiation. 3. Synchronous bilateral breast cancer. 4. Patients treated by radical mastectomy. 5. Patients with neoadjuvant therapy. 6. Patients with previous or concomitant other (not breast cancer) malignancy within the past 3 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients who have had a previous other malignancy must have been disease free for at least three years. 7. Patients with other unstable or untreated non-malignant systemic diseases (cardiovascular, renal, hepatic, lung embolism, etc.) which would prevent prolonged follow-up. 8. Patients treated with systemic investigational drugs within the past 30 days
Conditions Breast Cancer
Phase NA
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to stratify women diagnosed with a lump in the breast by clinical breast examination(CBE) using a hand-held ultrasound machine. They will be stratified either with benign or potentially malignant lesion. As most of the lesions identified by CBE are benign, stratifying them (triage) avoids the unnecessary procedures in terms of mammography and biopsy. This will also reduce the burden in the further assessment sites, and provide better quality services in these places.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Portable ultrasound device — The women detected with a breast lump on clinical breast examination will be examined using a portable ultrasound device by a trained medical officer at the primary healthcare facility, to traige them

Primary Outcomes

  • Positive predictive value and negative predictive value of CBE by ultrasound triaging (From recruitment to 30 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-01
Completion: 2028-04-30
Eligibility
Age: 30 Years – 69 Years
Sex: FEMALE
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: International Agency for Research on Cancer
Collaborators: Dharmais National Cancer Center Hospital
Contact Information
Study Contact:
Kardinah Kardinah
+62 21 5681570
kardinahrskd@gmail.com
Dharmais hospital
Kardinah Kardinah
Dharmais hospital
Interventions
  • Diagnostic Test: Portable ultrasound device — The women detected with a breast lump on clinical breast examination will be examined using a portable ultrasound device by a trained medical officer at the primary healthcare facility, to traige them
Study Locations (1 sites)
Dharmais hospital, Jakarta, West Jakarta 11420 Indonesia
Eligibility Criteria
Inclusion Criteria: * Women eligible for breast cancer screening as per the National screening programme in the country, and those detected with a breast lump on clinical breast examination Exclusion Criteria: * Women already screened in the last three years * Women with known history of breast cancer or breast surgery * Symptomatic with high probability of breast cancer diagnosis (ulcerated lump, blood-stained nipple discharge etc.) * Debilitating illness * Unable to provide informed consent due to certain mental illnesses * Unlikely to be compliant to study procedures and/or follow up as determined by the investigator
Conditions Breast Cancer, Prostate Cancer
Phase NA
Enrollment 1750
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

Many people with cancer spend a lot of time and money traveling to and from the doctor's office for cancer care. MSK's goal is to make getting cancer care easier by cutting down the need to make in-person visits to MSK. MSK is trying to do this through a new option called enhanced telehealth.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: Usual practice pattern (UPP) — Patient follows usual practice pattern for routine care
  • Other: Experimental: Enhanced Telehealth (ET) — Patient follows enhanced telehealth practice pattern. As clinically appropriate, patients given option to shift routine care from face-to-face to at-home services available at institution: telehealth visits, home phlebotomy, and educational support for home administration of injection medications

Primary Outcomes

  • Proportion of routine face to face medical oncology related visits out of total medical oncology related visits (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-01
Completion: 2027-05-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1750 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigators:
  • Erin Bange, MD, MSCE (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Erin Bange, MD, MSCE
646-422-4680
bangee@mskcc.org
Deborah Schrag, MD, MPH
212-639-5851
Erin Bange, MD, MSCE
646-422-4680
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Interventions
  • Other: Usual practice pattern (UPP) — Patient follows usual practice pattern for routine care
  • Other: Experimental: Enhanced Telehealth (ET) — Patient follows enhanced telehealth practice pattern. As clinically appropriate, patients given option to shift routine care from face-to-face to at-home services available at institution: telehealth visits, home phlebotomy, and educational support for home administration of injection medications
Study Locations (7 sites)
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey 07920 United States
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey 07748 United States
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey 07645 United States
Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack, New York 11725 United States
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York 10604 United States
Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York, New York 10065 United States
Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York 11553 United States
Eligibility Criteria
Inclusion Criteria: * Patients with breast or prostate cancer at Memorial Sloan Kettering Cancer Center who have had at least 3 prior medical oncology visits. Exclusion Criteria: * Patient is enrolled on a therapeutic clinical trial. * Patients whose primary language is not currently supported by Epic.
Conditions Breast Cancer, Breast Neoplasm, Chemothe...
Phase NA
Enrollment 130
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if an Arabic-language mobile application that uses artificial intelligence (AI) can help women with breast cancer during chemotherapy. The app is designed to give personalized support by reminding participants about their medications, teaching them how to manage treatment side effects, and alerting their healthcare team about serious symptoms. The main questions this study aims to answer are: 1. Does the AI-based mobile app provide accurate and safe recommendations for the patients? 2. Does using the AI-based mobile app help lower treatment-related symptoms and side effects compared to usual care? 3. Does the app help participants take their medications more regularly? 4. Does it increase participants' understanding and satisfaction with the information they receive about their treatment? Researchers will compare two groups: Group 1: Participants who use the AI-based mobile app plus usual oncology care. Group 2: Participants who receive usual care only. Participants will: 1. Use the mobile app daily for 12 weeks while receiving chemotherapy. 2. Complete short questionnaires about symptoms, medication use, and quality of life at the start and end of the study. 3. Report any problems or feedback about using the app. The AI app is for support and education only. It does not make treatment decisions. All information from the app will be reviewed by oncologists and pharmacists to ensure participant safety.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: AI-Based Mobile Application for Personalized Chemotherapy Support — The intervention is an Arabic-language mobile application powered by artificial intelligence (AI) designed to provide personalized chemotherapy support for women with breast cancer. The app assists participants by monitoring symptoms, sending medication adherence reminders, and offering educational content on managing side effects and improving treatment understanding. It uses a conversational interface based on natural language processing (NLP) to communicate with users. Participants are asked to use the app daily for 12 weeks while receiving chemotherapy. A human-in-the-loop system ensures oncologists and pharmacists review AI-generated advice for accuracy and safety.
  • Other: Usual Care — Standard oncology care provided by the hospital team, including chemotherapy administration, routine follow-up, and patient education according to local protocols.

Primary Outcomes

  • Change in Symptom Burden and Chemotherapy-Related Toxicities (Arabic PRO-CTCAE) (Up to 12 weeks)
  • Medication Adherence Score (Arabic MMAS-8 (Baseline and at weeks 6,12.)
  • Change in Patient Knowledge and Information Satisfaction (EORTC QLQ-INFO25) (Baseline and at weeks 6,12.)
  • Change in General Quality of Life (EORTC QLQ-C30) (Baseline and at weeks 6,12.)
  • Change in Breast Cancer-Specific Quality of Life (EORTC QLQ-BR23) (Baseline and at weeks 6,12.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-01
Completion: 2026-11-06
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 130 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dena h. Al-Tameemi
Collaborators: Baghdad Medical City
Principal Investigators:
  • Samer Imad Mohammed, Assistant Prof (PRINCIPAL_INVESTIGATOR) - University of Baghdad-College of Pharmacy
Contact Information
Study Contact:
Dena A. Al-Tameemi, MSc.
+9647901572647
dina.abbas2400p@copharm.uobaghdad.edu.iq
Samer Imad Mohammed, PhD
Samer.jameel@copharm.uobag
Rasha Saer Abbood, F.I.B.M.S med.oncology
009647813281259
Drrasha85@yahoo.com
Oncology Teaching Hospital-Medical City- Baghdad
Interventions
  • Behavioral: AI-Based Mobile Application for Personalized Chemotherapy Support — The intervention is an Arabic-language mobile application powered by artificial intelligence (AI) designed to provide personalized chemotherapy support for women with breast cancer. The app assists participants by monitoring symptoms, sending medication adherence reminders, and offering educational content on managing side effects and improving treatment understanding. It uses a conversational interface based on natural language processing (NLP) to communicate with users. Participants are asked to use the app daily for 12 weeks while receiving chemotherapy. A human-in-the-loop system ensures oncologists and pharmacists review AI-generated advice for accuracy and safety.
  • Other: Usual Care — Standard oncology care provided by the hospital team, including chemotherapy administration, routine follow-up, and patient education according to local protocols.
Study Locations (1 sites)
Oncology Teaching Hospital-Medical City- Baghdad, Baghdad, Iraq
Eligibility Criteria
Inclusion Criteria: * Confirmed diagnosis of breast cancer stages I, II, or III. * Patients must be currently scheduled to initiate their first-ever cycle of chemotherapy. * Age 18 years or older. * Ability to understand and provide informed consent. * Possession of a smartphone (Android or iOS) and functional digital literacy, defined as the ability to independently navigate mobile applications, read on-screen text in Arabic, and input daily health data. (for the intervention group). * Willingness to comply with study procedures and follow-up schedules. * Ability to communicate in Arabic, as the mobile application and chatbot will be developed in Arabic. Exclusion Criteria: * Patients with Stage IV (Metastatic) breast cancer. * Patients receiving concurrent hormonal therapy during the chemotherapy phase, to isolate chemotherapy-induced adverse events. Patients with cognitive impairment or severe psychiatric disorders that would preclude effective interaction with the mobile application or questionnaire completion. * Patients receiving palliative care where symptom management is the sole focus and active chemotherapy is not being administered with curative or life prolonging intent. * Patients participating in other interventional clinical trials that might confound the outcomes of this study. * Patients with severe comorbidities that could significantly impact their ability to participate or bias outcome measures.
Conditions Lymphedema, Breast Cancer
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of the investigators is to develop an integrated algorithm for surgical treatment of chronic lymphedema after breast cancer surgery. This will be achieved by retrospectively analysing a subgroup of patients who had breast cancer-related surgery prior to lymphedema.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Primary Outcomes

  • To design an integrated algorithm for surgical treatment of chronic lymphedema after breast cancer surgery. (baseline to follow up (no later than December 2024))
  • Date of follow-up procedure (baseline to follow up (no later than December 2024))
  • Follow-up and type of lymphedema surgery (baseline to follow up (no later than December 2024))
  • Circumferences of the affected and unaffected side (baseline to follow up (no later than December 2024))
  • Postoperative complications (baseline to follow up (no later than December 2024))
  • Surgery duration. (baseline to follow up (no later than December 2024))
  • Type of lymphedema surgery (baseline to follow up (no later than December 2024))
  • Date of lymphedema surgery (baseline to follow up (no later than December 2024))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2015-01-02
Completion: 2035-12-31
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Basel, Switzerland
Collaborators: Sana Kliniken Düsseldorf GmbH
Principal Investigators:
  • Elisabeth A Kappos, PD Dr. med (PRINCIPAL_INVESTIGATOR) - USB
Contact Information
Study Contact:
Elisabeth A Kappos, PD Dr. med
0041 61 265 25 25
elisabeth.kappos@usb.ch
Adriano Fabi, BMed
0041 79 888 12 51
adriano.fabi@uzh.ch
Elisabeth A Kappos, PD Dr. med.
0041 61 265 25 25
elisabeth.kappos@usb.ch
University Hospital Basel
Interventions
N/A
Study Locations (1 sites)
University Hospital Basel, Basel, 4031 Switzerland
Eligibility Criteria
Inclusion Criteria: * status post breast cancer or status post another type of cancer or status post no cancer * chronic lymphedema - lymphedema lasting over three months - present prior to surgical treatment * one type of surgical procedure for treatment of chronic lymphedema or a combination of surgical procedures for treatment of chronic lymphedema was performed * one or any combination of the following surgical procedures was used in each individual patient: Lymph Node-Vein Anastomosis (LNVA) , Lymphaticovenous Anastomosis (LVA), Tumescent Liposuction (TL), Vascularized Lymph Node Transfer (VLNT) and/or Water-Assisted Liposuction (WAL) Exclusion Criteria: * inclusion criteria not met * loss to follow-up (data not successfully collected)
Conditions Anatomic Stage IV Breast Cancer AJCC v8,...
Phase NA
Enrollment 739
Locations 723 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: Usual care disease monitoring — Imaging and serum tumor markers are at the discretion of the treating physician (however imaging must be performed at least every 12 weeks).
  • Other: Serum Tumor Marker directed disease monitoring — Serum tumor markers every 4-8 weeks without imaging
  • Other: Quality-of-Life Assessment — Ancillary studies
  • Other: Anxiety Questionnaire Administration — Ancillary studies

Primary Outcomes

  • Assessment of whether patients monitored with STMDDM have non-inferior overall survival compared with patients monitored with usual care (Up to 312 weeks after randomization)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2018-09-17
Completion: 2036-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 739 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Melissa Accordino (PRINCIPAL_INVESTIGATOR) - SWOG Cancer Research Network
Contact Information
Study Contact:
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org
Anchorage Associates in Radiation Medicine
Charles W. Drescher
Anchorage Associates in Radiation Medicine
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org
Anchorage Radiation Therapy Center
Interventions
  • Other: Usual care disease monitoring — Imaging and serum tumor markers are at the discretion of the treating physician (however imaging must be performed at least every 12 weeks).
  • Other: Serum Tumor Marker directed disease monitoring — Serum tumor markers every 4-8 weeks without imaging
  • Other: Quality-of-Life Assessment — Ancillary studies
  • Other: Anxiety Questionnaire Administration — Ancillary studies
Study Locations (723 sites)
Anchorage Associates in Radiation Medicine, Anchorage, Alaska 98508 United States
Anchorage Radiation Therapy Center, Anchorage, Alaska 99504 United States
Alaska Breast Care and Surgery LLC, Anchorage, Alaska 99508 United States
Alaska Oncology and Hematology LLC, Anchorage, Alaska 99508 United States
Alaska Women's Cancer Care, Anchorage, Alaska 99508 United States
Anchorage Oncology Centre, Anchorage, Alaska 99508 United States
Katmai Oncology Group, Anchorage, Alaska 99508 United States
Providence Alaska Medical Center, Anchorage, Alaska 99508 United States
Fairbanks Memorial Hospital, Fairbanks, Alaska 99701 United States
Kingman Regional Medical Center, Kingman, Arizona 86401 United States
Eligibility Criteria
Inclusion Criteria: * STEP 1 REGISTRATION * Patients must have a diagnosis of hormone receptor positive (estrogen receptor positive \[ER+\] and/or progesterone receptor positive \[PR+\]), HER-2 negative, metastatic (M1) breast cancer and must be receiving or plan to receive first-line systemic treatment for metastatic disease. (Systemic treatment is any treatment meant to treat the whole body such as endocrine therapy +/- targeted therapy +/- chemotherapy). * NOTE: Participants are eligible if they have either de-novo metastatic breast cancer and/or recurrent breast cancer from an earlier stage that is now metastatic * Patients must be registered to step 1 between 14 days prior to and 60 days after start of first-line systemic treatment for metastatic disease * Patients must have been tested for the following breast cancer specific STMs after diagnosis of metastatic disease and within +/-14 days of initiation of first-line systemic treatment for metastatic disease: * CEA (must be tested) * CA 15-3 or CA 27.29 (at least one of these must be tested) * At least one of the tested STMs must have been \>= 1.5 x the institutional upper limit of normal at this time. Testing all three STMs is encouraged but only two are required. Patients must plan to have the same two STMs tested for the duration that the patient is on protocol-specified disease monitoring. * Patients must have systemic radiographic imaging prior to initiation of systemic therapy or within 30 days of initiation of treatment for metastatic breast cancer and prior to step 1 registration. Modality of imaging is at the discretion of the treating physician. * Note: the treating physician can order additional imaging tests at any point prior to randomization at their discretion * Patients must be willing to obtain disease monitoring (imaging and/or serum tumor markers) from a consistent facility in which the registering site has access to the results for the duration of the study intervention (312 weeks after step 2 randomization). Imaging and STMs do not need to be completed at the same facility. * Patients with known cirrhosis, untreated B12 deficiency, thalassemia, or sickle cell anemia are not eligible as these could cause falsely elevated STM levels * Patients with known brain leptomeningeal metastases are not eligible as they may require regular radiographic monitoring to assess treatment response * Patients must not be currently enrolled or plan to participate in a first-line treatment trial for metastatic breast cancer with a defined monitoring schedule * Patients who are able to complete questionnaires in English or Spanish must participate in patient-reported outcome (PRO) assessments * Patients must not be pregnant due to the potential harm to the fetus from radiation exposure from radiographic imaging * Except for breast cancer (and previous history of breast cancer), no other prior malignancy is allowed with the following exceptions: * Adequately treated basal (or squamous cell) skin cancer * Any cancer from which the patient has been disease free for five years * Prior Stage 0 or pre-cancerous lesions that have been removed with clear margins * Patients must not have received prior systemic therapy for metastatic breast cancer, except for their current line of therapy. * Patients must have decision making capacity and be able to provide informed consent * Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines; use of legally-authorized representative is not permissible for this study. Remote consent is allowed with adequate documentation. * As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system * STEP 2 RANDOMIZATION * Patients must be tested for the breast cancer specific STMs that were tested prior to STEP 1 Registration between 56 and 140 days after initiation of first-line systemic therapy for metastatic disease: * CEA (must be tested) * CA 15-3 or CA 27.29 (whichever was tested prior to Step 1) Testing all three STMs is encouraged but only two are required. Patients must plan to have the same two STMs tested for the duration that the patient is on protocol-specified disease monitoring. * At least one of the STMs that was previously elevated must have decreased from the assessment at step 1 by \>= 10% at this time. * Patients must not have known progression since registration to step 1 * Patients must be registered to step 2 randomization between 56 days and 140 days after the initiation of first-line systemic therapy for metastatic disease; This window is inclusive; patients may be registered to Step 2 on day 56 or Day 140. Patients must have been eligible for Step 1 in order to be eligible for Step 2 Randomization * Baseline questionnaires must be completed within 28 days prior to step 2 randomization; (Note: Those patients who cannot complete the PRO questionnaires in English or Spanish can be registered to step 2 without contributing to PRO research)
Conditions Breast Cancer Risk, Ovarian Cancer Risk,...
Phase NA
Enrollment 6000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

PROTECT-C is a research study offering genetic testing to people to see whether they have a genetic change that increases their risk of breast, ovary, bowel, and/or womb cancer. This is regardless of whether they or their families have had cancer. Breast, ovary, bowel, and womb cancers make up half of all cancers in women. Around 15-20% (15 to 20 in 100 cases) of ovary and 3-4% (3 to 4 in 100 cases) of breast, womb, and bowel cancers are linked to cancer genes and may be prevented. People with a genetic change that puts them at increased risk of any of these cancers have ways to help them manage their risk through the NHS. This may include screening to find cancers earlier when they are easier to treat, and surgery or medication to prevent cancers from developing. This can save lives. Currently, genetic testing is only available on the NHS to people who meet certain criteria. For example, those who have had certain cancers, have a strong family history of cancer, or those with Jewish ancestry. But many people may not have a strong family history or meet NHS testing criteria. This means that this system of testing misses 50% to 80% of people (50 to 80 in 100 people) who have a genetic change. It is thought that only around 3 in 100 people overall who have a genetic change that increases their risk of cancer know about it. Given the effective screening and preventive options that are available, this represents a huge, missed opportunity to prevent cancers or find them earlier. The PROTECT-C study aims to evaluate the option of offering genetic testing to everyone who may want it. This is regardless of whether they or their families have had cancer. We will offer genetic testing to 5000 people. People may take part if they: * Are over the age of 18 years and * Are a woman, trans man, or non-binary person with female reproductive organs (ovaries, fallopian tubes, and/or a uterus) and * Have never had genetic testing for the cancer genes tested for in the study and * Do not have first-degree family members (e.g.: parent, sibling, child) or second-degree family members (e.g.: aunt, uncle, niece, nephew, grandchild, grandparent, half-sibling) with genetic changes in the cancer genes tested for in the study PROTECT-C is a completely digital study. The study team will give participants access to an app developed specifically for this study. They can download this app using a smartphone or tablet or access it on any internet browser using a computer or laptop. Before they can access the app, participants will need to complete a consent form. They will also be asked to fill in a short questionnaire about themselves and their health. The PROTECT-C app contains information to help participants decide if they would like to have genetic testing. If they decide to have genetic testing, they will complete a consent form for genetic testing on the app. The study team will send them a saliva based test kit in the post. The study will look at how many people…

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Genetic: Genetic testing for Cancer Susceptibility Genes (CSGs) (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2, MLH1, MSH2, MSH6) and personalised breast and ovarian cancer risk — Genetic testing for Cancer Susceptibility Genes (CSGs) (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2, MLH1, MSH2, MSH6) and personalised breast and ovarian cancer risk for all women (including trans-men, and non-binary individuals with female reproductive organs) over the age of 18 years independent of any family or personal history of cancer.

Primary Outcomes

  • Pathogenic variant (PV) prevalence for multiple moderate to high penetrance CSGs (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2, MLH1, MSH2, MSH6) in women from unselected population-based genetic testing compared with FH-based genetic testing (1 year after completing recruitment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-18
Completion: 2040-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 6000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Queen Mary University of London
Collaborators: University of Cambridge, University of Manchester, London School of Hygiene and Tropical Medicine, Institute of Cancer Research, United Kingdom, University of Leeds, Imperial College London, University College, London, VU University Medical Center (VUmc), St George's, University of London
Principal Investigators:
  • Ranjit Manchanda, PhD (PRINCIPAL_INVESTIGATOR) - Wolfson Institute of Population Health, Queen Mary University of London
Contact Information
Study Contact:
Ranjit Manchanda, PhD
+44 8008620236
r.manchanda@qmul.ac.uk
Caitlin Fierheller, PhD
+44 8008620236
protectc.study@qmul.ac.uk
Ranjit Manchanda, PhD
+44 8008620236
r.manchanda@qmul.ac.uk
Wolfson Institute of Population Health, Queen Mary University of London
Interventions
  • Genetic: Genetic testing for Cancer Susceptibility Genes (CSGs) (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2, MLH1, MSH2, MSH6) and personalised breast and ovarian cancer risk — Genetic testing for Cancer Susceptibility Genes (CSGs) (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2, MLH1, MSH2, MSH6) and personalised breast and ovarian cancer risk for all women (including trans-men, and non-binary individuals with female reproductive organs) over the age of 18 years independent of any family or personal history of cancer.
Study Locations (1 sites)
Wolfson Institute of Population Health, Queen Mary University of London, London, EC1M 6BQ United Kingdom
Eligibility Criteria
Inclusion Criteria: * Women, trans men, and non-binary people with female reproductive organs * ≥18 years at consent Exclusion Criteria: * Individuals who have previously undergone genetic testing for one or more of the following CSGs: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BRIP1, MLH1, MSH2, MSH6 * One or more first- or second-degree relative with a PV in any of above CSGs * Inability to provide informed consent
Conditions Breast Cancer, Metastatic Breast Cancer,...
Phase PHASE3
Enrollment 404
Locations 79 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: SV-BR-1-GM — SV-BR-1-GM is an experimental, allogeneic, whole cell breast tumor cell line stably transfected with the CSF2 gene (encoding GM-CSF) to secrete GM-CSF in vivo to consequently augment dendritic cell activity
  • Drug: Cyclophosphamide — Cyclophosphamide is an alkylating agent with indications for treatment of malignant diseases including breast cancer. Cyclophosphamide (Cytoxan) 300 mg/m2 I.V., single dose, will be given to patients assigned to the SV-BR-1-GM. Cyclophosphamide will be administered 2-3 days prior to SV-BR-1-GM inoculations.
  • Drug: Interferon infiltration of the inoculation site — Interferon is a cytokine released by cells to regulate immune responses to viral infections. For this study, 0.1 mcg Pegasys per injection site (x 4 injection sites) will be administered.
  • Drug: Retifanlimab — Retifanlimab is a checkpoint inhibitor. A total dose of 375mg will be administered at first cycle on or about day +2 (+/-1d). In all other cycles, Retifanlimab is permitted to be administered between Day -2/-3 to Day 2±1 of the cycle based on the convenience of the patients and the clinical sites. However once the timing of the CPI is chosen for C1, it must be given on the same day thereafter throughout the trial.
  • Drug: Treatment of Physician's Choice — Patients in the TPC arm of the study will be treated with one or a combination of the following: carboplatin, taxanes, capecitabine, gemcitabine, vinorelbine or eribulin in accordance with the investigators and institutional standard of care. For HER2+ patients, a HER2-targeted agent of the physician's choice can be part of TPC.

Primary Outcomes

  • Overall Survival (Up to 60 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-12-05
Completion: 2028-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 404 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: BriaCell Therapeutics Corporation
Principal Investigators:
  • Giuseppe Del Priore, MD MPH (STUDY_DIRECTOR) - BriaCell Therapeutics
Contact Information
Study Contact:
Malobika Bhowmick
1-888-485-6340
mbhowmick@briacell.com
Marcela Salgado, MD
1-888-309-1868
MSalgado@briacell.com
Alicia Ortiz, CCRC
480-574-2802
ortiz.alicia@mayo.edu
Mayo Clinic-Comprehensive Cancer Center-Breast Clinic
Interventions
  • Biological: SV-BR-1-GM — SV-BR-1-GM is an experimental, allogeneic, whole cell breast tumor cell line stably transfected with the CSF2 gene (encoding GM-CSF) to secrete GM-CSF in vivo to consequently augment dendritic cell activity
  • Drug: Cyclophosphamide — Cyclophosphamide is an alkylating agent with indications for treatment of malignant diseases including breast cancer. Cyclophosphamide (Cytoxan) 300 mg/m2 I.V., single dose, will be given to patients assigned to the SV-BR-1-GM. Cyclophosphamide will be administered 2-3 days prior to SV-BR-1-GM inoculations.
  • Drug: Interferon infiltration of the inoculation site — Interferon is a cytokine released by cells to regulate immune responses to viral infections. For this study, 0.1 mcg Pegasys per injection site (x 4 injection sites) will be administered.
  • Drug: Retifanlimab — Retifanlimab is a checkpoint inhibitor. A total dose of 375mg will be administered at first cycle on or about day +2 (+/-1d). In all other cycles, Retifanlimab is permitted to be administered between Day -2/-3 to Day 2±1 of the cycle based on the convenience of the patients and the clinical sites. However once the timing of the CPI is chosen for C1, it must be given on the same day thereafter throughout the trial.
  • Drug: Treatment of Physician's Choice — Patients in the TPC arm of the study will be treated with one or a combination of the following: carboplatin, taxanes, capecitabine, gemcitabine, vinorelbine or eribulin in accordance with the investigators and institutional standard of care. For HER2+ patients, a HER2-targeted agent of the physician's choice can be part of TPC.
Study Locations (79 sites)
Mayo Clinic-Comprehensive Cancer Center-Breast Clinic, Phoenix, Arizona 85054 United States
University of Arizona-Cancer Center, Tucson, Arizona 85719 United States
Los Angeles cancer Network_Anaheim, Anaheim, California 92801 United States
Comprehensive Blood and Cancer Center, Bakersfield, California 93309 United States
Cedars-Sinai Cancer Beverly Hills, Beverly Hills, California 90211 United States
Los Angeles Cancer Network_Corona, Corona, California 92879 United States
Los Angeles cancer Network_Fountain Vallley, Fountain Valley, California 92708 United States
Los Angeles Cancer Network_Glendale, Glendale, California 91206 United States
Hoag Hospital Center, Irvine, California 92618 United States
Hoag Hospital Irvine, Irvine, California 92618 United States
Eligibility Criteria
Inclusion Criteria: 1. Be ≥ 18 years of age. 2. Have signed informed consent. 3. Have histological confirmation of breast cancer with either locally recurrent unresectable and/or metastatic lesions, and have failed prior therapy: * Patients with persistent disease and local recurrence must not be amenable to local treatment. * For patients with metastatic disease, late-stage MBC with no meaningful alternative therapies available and the following class specific treatment histories: 1. Human epidermal growth factor 2 (HER2) positive must be previously treated with at least 3 regimens containing at least two anti-HER2 and at least one chemotherapy containing regimen. 2. Estrogen receptor (ER), progesterone receptor (PR) positive tumors: must be refractory to hormonal therapy demonstrated by progression on at least 2 hormonal agents in 2 separate lines of hormone directed therapy. 3. Triple Negative tumors: Must have exhausted all curative intent therapies including at least 2 prior chemotherapy regimens, which can include regimens in neoadjuvant and adjuvant settings. 4. Cancers with known germline or genomic actionable targets, e.g. g/mBRCA, must have been treated with all tumor directed indicated treatment e.g. PARPi, if tolerated. 5. HER2 low patients, in addition to the appropriate therapies based on ER/PR status and germline or genomic actionable targets, must also have received at least one HER2-targeted agent approved for treatment of HER2 low patients. 6. HER2 negative tumors must be refractory to hormonal therapy (if indicated) and previously treated with at least 2 chemotherapy regimens. 7. Patients with new or progressive breast cancer metastatic to the brain will be eligible provided: * The brain metastases must be clinically stable (without evidence of progressive disease by imaging for at least 4 weeks prior to first dose) * There is no need for steroids and patients have not had steroids for at least 2 weeks prior to the first dose * Tumor is not impinging on Middle Cerebral Artery/speech-motor strip * If surgically debulked, must be healed with at least 3 weeks since surgery prior to the first dose 4. Has expected survival of at least 4 months. 5. ECOG performance status of 0, 1 or 2 Exclusion Criteria: 1. Concurrent or recent chemotherapy, immunotherapy or major surgery within 21 days prior to the first dose. 2. Radiotherapy within 14 days of the first dose of study treatment. 3. Toxicity of prior therapy that has not recovered to ≤ Grade 1 or baseline (with the exception of any grade of alopecia and anemia not requiring transfusion support). 4. Any toxicity to prior CPI that was grade 3 or higher unless it has been successfully treated (e.g. hypothyroidism or hypopituitarism treated with replacement therapy), . 5. Toxicity to prior CPI that has not resolved to grade 1 or less except for stable asymptomatic endocrinopathies. 6. History of clinical hypersensitivity to the designated therapy as specified in the protocol, including the proposed TPC, beef, or to any components used in the preparation of SV- BR-1-GM. 7. History of hypersensitivity to any of the therapies proposed for treatment in this study. 8. Serum creatinine OR Measured OR calculated Creatinine Clearance (CrCl) (GFR can also be used in place of creatinine or CrCl) \>2.0 × ULN or \<30 mL/min for participants with creatinine levels \>2.0 × institutional ULN. 9. Absolute granulocyte count \<1000; platelets \<80,000; hemoglobin ≤ 7 g/L. 10. Bilirubin ≥ 2 × ULN unless conjugated bilirubin ≤ ULN; alkaline phosphatase \>5x upper limit of normal (ULN); ALT/AST \>3x ULN. For patients with hepatic metastases, ALT/AST \>5x ULN is exclusionary. 11. INR or PT or aPTT \> 1.8 × ULN, unless the participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants. 12. Receiving any medication listed in the prohibited medication section of the protocol. 13. Proteinuria \>2+ on urinalysis 14. A history or presence of an abnormal electrocardiogram (ECG) that, in the Investigator's opinion, is clinically meaningful. Screening corrected QT interval (QTc) interval \>480 milliseconds is excluded (corrected by Fridericia or Bazett formula). In the event that a single QTc is \>480 milliseconds, the participant may enroll if the average QTc for the 3 ECGs is \<480 milliseconds. 15. New York Heart Association stage 3 or 4 cardiac disease. 16. A pericardial effusion of moderate severity or worse. 17. Symptomatic pleural effusion or ascites. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible. 18. Any woman of childbearing potential (i.e., has had a menstrual cycle within the past year and has not been surgically sterilized), unless she agrees to take appropriate precautions to avoid becoming pregnant during the study and has a negative serum pregnancy test within 7 days prior to starting treatment. 19. Men must have been sterile or, if they were potentially fertile/reproductively competent, should take appropriate precautions to avoid fathering a child for the duration of the study. 20. Women who are pregnant or nursing. 21. Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry with the exception of cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy, or cancers from which the participant has been disease-free for \> 1 year, after treatment with curative intent. 22. Patients who have uncontrolled HIV or have clinical or laboratory features indicative of AIDS. 23. Have a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. 24. Have an active autoimmune disease that has required systemic treatment in past year (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is allowed. 25. Known active HAV, HBV, or HCV infection, as defined by elevated transaminases with the following serology: positivity for HAV IgM antibody, anti-HCV, anti-HBc IgG or IgM, or HBsAg (in the absence of prior immunization). 26. Active infections requiring systemic therapy within the past 14 days. 27. Patients with severe psychiatric disease (e.g., schizophrenia, bipolar, or borderline personality disorder) or other clinically progressive major medical problems, unless approved by the Investigator in consultation with the Medical Monitor. 28. Has received a live vaccine within 28 days of the first dose of study drug. 29. Patients may not be on a concurrent clinical trial, unless approved by the Investigator.
Conditions Anatomic Stage II Breast Cancer AJCC v8,...
Phase PHASE3
Enrollment 1295
Locations 846 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. The usual approach for patients with early-stage TNBC who receive preoperative chemotherapy plus pembrolizumab is to continue to receive pembrolizumab for up to 27 weeks after surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation is as good as receiving pembrolizumab for 27 weeks after surgery in triple-negative breast cancer patients who achieved a pathologic complete response after preoperative treatment with chemotherapy and pembrolizumab.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: Pembrolizumab — Given IV
  • Other: Patient Observation — Undergo observation
  • Procedure: Biopsy — Undergo biopsy
  • Procedure: Biospecimen Collection — Undergo collection of blood
  • Other: Questionnaire Administration — Ancillary studies
  • Other: Quality-of-Life Assessment — Ancillary studies

Primary Outcomes

  • Recurrence-free survival (RFS) (Up to 10 years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-06-14
Completion: 2033-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1295 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)
Contact Information
Study Contact:
Sara Tolaney, MD
617-632-2335
Sara_Tolaney@dfci.harvard.edu
Laura Hoffman
773-834-2546
lhoffman22@bsd.uchicago.edu
Site Public Contact
251-435-4584
Thomas Hospital
Interventions
  • Biological: Pembrolizumab — Given IV
  • Other: Patient Observation — Undergo observation
  • Procedure: Biopsy — Undergo biopsy
  • Procedure: Biospecimen Collection — Undergo collection of blood
  • Other: Questionnaire Administration — Ancillary studies
Study Locations (846 sites)
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama 35233 United States
Thomas Hospital, Fairhope, Alabama 36532 United States
Mobile Infirmary Medical Center, Mobile, Alabama 36607 United States
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama 36688 United States
Katmai Oncology Group, Anchorage, Alaska 99508 United States
CTCA at Western Regional Medical Center, Goodyear, Arizona 85338 United States
Kingman Regional Medical Center, Kingman, Arizona 86401 United States
Cancer Center at Saint Joseph's, Phoenix, Arizona 85004 United States
Mayo Clinic Hospital in Arizona, Phoenix, Arizona 85054 United States
Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas 72703 United States
Eligibility Criteria
Inclusion Criteria: * Age \>= 18 years * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 * Triple Negative Breast Cancer: * Patients with a history of clinical stage T1cN1-2 or T2-4N0-2 (clinical stage II or III prior to preoperative therapy) breast cancer at time of diagnosis according to the primary tumor-regional lymph node anatomic staging criteria of the American Joint Committee on Cancer (AJCC), 8th edition as determined by the investigator in radiologic assessment, clinical assessment or both * Patients must have no residual invasive disease in the breast or lymph nodes after the completion of neoadjuvant therapy. Residual ductal carcinoma in situ (DCIS) is allowed. Isolated tumor cells are considered node-negative * Estrogen receptor (ER) and progesterone receptor (PR) =\< 10%; HER2-negative by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines (immunohistochemistry \[IHC\] and fluorescence in situ hybridization \[FISH\]) * If invasive disease was present in both breasts, participation in the study is permitted as long as the eligibility criteria are met for both tumors/breasts * Patients must have received neoadjuvant chemotherapy in combination with pembrolizumab for a minimum of 6 cycles. All systemic chemotherapy must have been completed preoperatively * An interval of no more than 12 weeks between the completion date of the final surgery and the date of randomization \* Note: Adjuvant radiation can be given on study, however, it is recommended to complete adjuvant radiation prior to registration. If radiation is given on study, it is encouraged to be given concurrently with pembrolizumab if the patient is on the pembrolizumab arm, per investigator discretion. Treatment with adjuvant pembrolizumab is strongly discouraged prior to participation in this trial, but if administered (e.g., if patients are awaiting pathology results), pembrolizumab may be administered for up to 6 weeks (i.e., up to 2 q3week doses or up to one q6week dose) post-surgery and must be completed prior to registration post-surgery and must be completed prior to registration * Use of investigational anti-cancer agents must be discontinued at time of registration * Adequate excision: Surgical removal of all clinically evident disease in the breast and lymph nodes as follows: * Breast surgery: Total mastectomy or breast-conserving surgery with histologically negative margins, including no ink on tumor for DCIS, at the time of excision \*\* For patients who undergo breast-conserving surgery, the margins of the resected specimen must be histologically free of ductal carcinoma in-situ (DCIS) as determined by the local pathologist. If pathologic examination demonstrates DCIS at the line of resection, additional operative procedures may be performed to obtain clear margins. If DCIS is still present at the resected margin after re-excision(s), the patient must undergo total mastectomy to be eligible. Patients with margins positive for classic lobular carcinoma in situ (LCIS) are eligible without additional resection * Lymph node surgery: * For a patient with clinically N0 disease, a sentinel lymph node biopsy should have been performed at time of surgical evaluation, and if pathologically node positive, the patient is no longer eligible. Isolated tumor cells are considered node-negative * For a patient with clinically N1 disease at diagnosis (with positive results from a fine-needle aspiration, core biopsy, or sentinel node biopsy performed prior to preoperative therapy) additional surgical evaluation of the axilla following preoperative therapy is required \*\*\* If they become cN0 (no palpable adenopathy), then a sentinel lymph node biopsy could have been performed at time of surgery (axillary dissection would also be permitted); if the sentinel lymph node biopsy is positive, the patient is no longer eligible * If sentinel node biopsy performed before preoperative therapy was negative, no additional surgical evaluation of the axilla is required after preoperative therapy. If sentinel node biopsy performed before preoperative therapy was positive, an ALND is required after preoperative therapy * If the only sentinel node identified by isotope scan is in the internal mammary chain, surgical evaluation of the axilla is still required * If sentinel node evaluation after preoperative therapy is negative, no further additional surgical evaluation of the axilla is required * Axillary dissection without sentinel node evaluation is permitted as the initial or sole axillary evaluation after preoperative therapy * If breast-conserving surgery was performed but patient will not be receiving breast radiation, the patient is not eligible * Not pregnant and not nursing, because this study involves an agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative serum or urine pregnancy test done =\< 7 days prior to randomization is required * Absolute neutrophil count (ANC) \>= 1,000/mm\^3 * Platelet Count \>= 100,000/mm\^3 * Estimated glomerular filtration rate (eGFR) \>= 15 mL/min/1.73m\^2 * Total Bilirubin =\<1.5 x upper limit of normal (ULN) \* Patients with Gilbert's disease with a total bilirubin =\< 2.5 x ULN and direct bilirubin within normal limits are permitted * Aspartate aminotransferase (AST) serum aspartate aminotransferase \[SGOT\] / alanine aminotransferase (ALT) serum glutamic pyruvic transaminase \[SGPT\] =\< 3 x institutional ULN * Patients must be willing to provide tumor tissue from the diagnostic core biopsy. If inadequate tumor tissue is available, patients are still eligible to participate in the trial * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better * Patients with known HIV infection who are on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial Exclusion Criteria: * No stage IV (metastatic) breast cancer * No history of any prior (ipsi- or contralateral) invasive breast cancer. Prior DCIS is allowed * No evidence of recurrent disease following preoperative therapy and surgery * No known active liver disease, e.g. due to hepatitis B virus (HBV), hepatitis C virus (HCV), autoimmune hepatic disorders, or sclerosing cholangitis * No history of intolerance, including Grade 3 or 4 infusion reaction or hypersensitivity to pembrolizumab or murine proteins or any components of the product \* Note: Prior immune-related adverse events (irAEs) are allowed if they resolved to ≤ grade 1 and the patient tolerated subsequent therapy without requiring chronic steroids for the irAE. The following are exceptions to this criterion: Grade 2 or lower immune mediated endocrinopathies due to neoadjuvant checkpoint inhibition but patients are stable on endocrine therapy and were able to continue checkpoint inhibition. * No medical conditions that require chronic systemic steroids (\>10 mg prednisone daily or equivalent) or any other form of immunosuppressive medications and has required such therapy in the last two years. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic therapy * Patients who are unable or unwilling to comply with the requirements of the protocol per investigator